BostonGene Secures $50 Million Series A Funding to Advance Cloud-Based Platform for Precision Cancer Treatment

VCBeat (WeChat ID: vcbeat) has learned that biomedical software company BostonGene recently completed a $50 million Series A financing round. The round was led by NEC Corporation, an IT and networking technology company. The funds will be used to support the company’s long-term development strategy, advance its biomedical information analysis platform, and expand its team.

BostonGene, founded in 2015 and headquartered in Boston, Massachusetts, USA, is a biomedical software company dedicated to developing precise, personalized treatment plans for cancer patients through cloud computing and artificial intelligence technologies. The company boasts a robust intellectual property portfolio and maintains close collaborations with numerous cancer centers across the United States.

BostonGene aims to integrate complex data analytics with scientific clinical knowledge to help physicians select optimal treatment plans and improve patient survival rates. The company pioneered the use of biomedical software for patient analysis and personalized medical decision-making, developing a cloud-based biomedical informatics analysis platform to enable precision cancer therapy.

The platform has created a database that aggregates the latest cancer research and clinical information from around the world. Updated daily, the database includes data on treatment response, patient prognosis, disease progression, therapeutic efficacy, and adverse reactions. By leveraging data analytics along with each patient’s individual genetic and disease characteristics, the company generates comprehensive, personalized treatment plans for physicians, thereby supporting improved clinical decision-making.

The platform’s capabilities include: generating patient molecular profiles based on genomic and transcriptomic sequencing methods; evaluating patients’ immune fitness and cancer characteristics using algorithms; continuously updating the cancer research and clinical information database powered by artificial intelligence; providing optimal treatment plans for patients based on comprehensive data analysis of tumor RNA and DNA; dynamically monitoring changes in tumor molecules to promptly adjust treatment regimens; offering personalized drug combinations; designing personalized vaccines; and predicting adverse reactions in patients.

Osamu Fujikawa, Senior Vice President and Head of the Business Innovation Division at NEC Corporation, stated, “Since its inception, BostonGene has demonstrated significant potential in the development of cancer immunotherapies and targeted therapies. Moving forward, we will leverage our corporate strengths to support BostonGene in developing a biomedical informatics analysis platform, thereby improving survival rates and quality of life for cancer patients.”

NEC Corporation (Tokyo Stock Exchange Code: 6701), founded on July 17, 1899, and headquartered in Tokyo, Japan, is a leader in the fields of IT and network technology. The company’s business operations and product offerings span numerous sectors, including telecommunications, manufacturing, retail, aerospace, transportation, biometric authentication, agriculture, and computing.

(Compiled by Jiao Yanli)